

COVID-19 Vaccine Recommendations

Immunocompromised Children: Administration of Primary Series and Booster Doses

Date: June 20, 2022



	Dose 1 (primary)		Dose 2 (primary)		Dose 3 (primary)		Dose 4		Dose 5
Pfizer (maroon cap) 6 months – 4 years	0.2 mL	Wait 3 weeks →	0.2 mL	Wait 8 weeks →	0.2 mL		NOT CURRENTLY RECOMMENDED		NOT CURRENTLY RECOMMENDED

	Dose 1 (primary)		Dose 2 (primary)		Dose 3 (additional dose) (primary)		Dose 4 (booster 1)		Dose 5 (booster 2)
Pfizer (orange cap) 5 – 11 years	0.2 mL	Wait 3 weeks →	0.2 mL	Wait 4 weeks →	0.2 mL	Wait 3 months →	0.2 mL		NOT CURRENTLY RECOMMENDED
Pfizer (gray or purple cap) 12 – 17 years	0.3 mL	Wait 3 weeks →	0.3 mL	Wait 4 weeks →	0.3 mL	Wait 3 months →	0.3 mL	Wait 4 months → Eligible Patients: - Ages 12 years and older who are moderately to severely immunocompromised	0.3 mL

	Dose 1 (primary)		Dose 2 (primary)		Dose 3 (additional dose) (primary)		Dose 4		Dose 5
Moderna (dark blue cap) 6 months – 5 years	0.25 mL	Wait 4 weeks →	0.25 mL	Wait 4 weeks →	0.25 mL		NOT CURRENTLY RECOMMENDED		NOT CURRENTLY RECOMMENDED